HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein

AIDS Research and Human Retroviruses

Volumn 28, Issue 7, 2012, Pages 715-724

  Baan, Elly ^a   De Ronde, Anthony ^a   Luchters, Stanley ^b   Vyankandondera, Joseph ^c   Lange, Joep M ^b   Pollakis, Georgios ^a   Paxton, William A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b IATEC   (Netherlands)

^c Centre Hospitalier Universitaire de Kigali   (Rwanda)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN GP 120;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHYLOGENY; PREGNANCY; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RWANDA; SEXUAL TRANSMISSION; VERTICAL TRANSMISSION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BREAST FEEDING; COHORT STUDIES; FEMALE; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOLECULAR SEQUENCE DATA; NEVIRAPINE; PREGNANCY; RWANDA; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 84863214078     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0023     Document Type: Article

References (47)

1. Kourtis AP, Lee FK, Abrams EJ, et al.: Mother-to-child transmission of HIV-1: Timing and implications for prevention. Lancet Infect Dis 2006;6(11):726-732. (Pubitemid 44601992)
2. Ometto L, Zanchetta M, Mainardi M, et al.: Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. AIDS 2000; 14(12):1721-1729.
3. Clevestig P, Maljkovic I, Casper C, et al.: The X4 phenotype of HIV type 1 evolves from R5 in two children of mothers, carrying X4, and is not linked to transmission. AIDS Res Hum Retroviruses 2005;21(5):371-378. (Pubitemid 40800453)
4. Reinhardt PP, Reinhardt B, Lathey JL, and Spector SA: Human cord blood mononuclear cells are preferentially infected by non-syncytium-inducing, macrophage-tropic human immunodeficiency virus type 1 isolates. J Clin Microbiol 1995; 33(2):292-297.
5. Shalekoff S, Gray GE, and Tiemessen CT: Age-related changes in expression of CXCR4 and CCR5 on peripheral blood leukocytes from uninfected infants born to human immunodeficiency virus type 1-infected mothers. Clin Diagn Lab Immunol 2004;11(1):229-234. (Pubitemid 38090681)
6. de Jong JJ, de RA, Keulen W, Tersmette M, and Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol 1992;66(11):6777-6780.
7. Hartley O, Klasse PJ, Sattentau QJ, and Moore JP: V3: HIVs switch-hitter. AIDS Res Hum Retroviruses 2005;21(2):171-189.
8. Pollakis G, Abebe A, Kliphuis A, et al.: Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 2004;78(6):2841-2852. (Pubitemid 38314342)
9. Matala E, Hahn T, Yedavalli VR, and Ahmad N: Biological characterization of HIV type 1 envelope V3 regions from mothers and infants associated with perinatal transmission. AIDS Res Hum Retroviruses 2001;17(18): 1725-1735. (Pubitemid 34114210)
10. Rainwater SM, Wu X, Nduati R, et al.: Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res 2007;5(2): 189-197. (Pubitemid 46488195)
11. Wu X, Parast AB, Richardson BA, et al.: Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006;80(2):835-844. (Pubitemid 43062895)
12. Blish CA, Blay WM, Haigwood NL, and Overbaugh J: Transmission of HIV-1 in the face of neutralizing antibodies. Curr HIV Res 2007;5(6):578-587. (Pubitemid 351210992)
13. Dickover R, Garratty E, Yusim K, et al.: Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol 2006;80(13):6525-6533. (Pubitemid 43927454)
14. Rong R, Bibollet-Ruche F, Mulenga J, et al.: Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 2007;81(3):1350-1359. (Pubitemid 46167856)
15. Pancera M, Majeed S, Ban YE, et al.: Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 2010;107(3):1166-1171.
16. Chackerian B, Rudensey LM, and Overbaugh J: Specific Nlinked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 1997;71(10):7719-7727. (Pubitemid 27391717)
17. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393(6686):648-659. (Pubitemid 28289647)
18. Pinter A, Honnen WJ, He Y, et al.: The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004;78(10):5205-5215. (Pubitemid 38581472)
19. Sagar M, Wu X, Lee S, and Overbaugh J: Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006;80(19):9586-9598. (Pubitemid 44435633)
20. Wyatt R, Moore J, Accola M, et al.: Involvement of the V1/ V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69(9):5723-5733.
21. Gray ES, Moore PL, Choge IA, et al.: Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007;81(12):6187-6196. (Pubitemid 46878025)
22. Geijtenbeek TBH, Kwon DS, Torensma R, et al.: DC-SIGN, a dendritic cell specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100(5):587-597.
23. Haase AT: Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005;5(10):783-792. (Pubitemid 41400852)
24. Hladik F and McElrath MJ: Setting the stage: host invasion by HIV. Nat Rev Immunol 2008;8(6):447-457. (Pubitemid 351735878)
25. Rappocciolo G, Piazza P, Fuller CL, et al.: DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog 2006;2(7):e70.
26. Luchters SMF, Veldhuijzen NJ, Nsanzabera D, et al.: A phase I/II, randomized, placebo controlled study to evaluate chloroquine administration for reduction of HIV-1 RNA in breast milk in an HIV-infected breastfeeding population, The CHARGE study. XV International AIDS Conference, 11-16 July 2004, Bangkok, Thailand, PeB4499.
27. Boom R, Sol CJ, Salimans MM, et al.: Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28(3):495-503. (Pubitemid 20078123)
28. Pollakis G, Kang S, Kliphuis A, et al.: N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 2001;276(16):13433-13441.
29. Renjifo B, Chung M, Gilbert P, et al.: In-utero transmission of quasispecies among human immunodeficiency virus type 1 genotypes. Virology 2003;307(2):278-282. (Pubitemid 36344161)
30. Renjifo B, Fawzi W, Mwakagile D, et al.: Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J Hum Virol 2001;4(1):16-25. (Pubitemid 32120416)
31. Koulinska IN, Villamor E, Msamanga G, et al.: Risk of HIV-1 transmission by breastfeeding among mothers infected with recombinant and non-recombinant HIV-1 genotypes. Virus Res 2006;120(1-2):191-198. (Pubitemid 43964968)
32. Salazar-Gonzalez JF, Bailes E, Pham KT, et al.: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008;82(8):3952-3970. (Pubitemid 351521232)
33. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al.: Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009;5(1):e1000274.
34. Abrahams MR, Anderson JA, Giorgi EE, et al.: Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009;83(8):3556-3567.
35. Schaaf GJ, Ruijter JM, van RF, et al.: Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: Statistical comparison of multiple SAGE libraries. FASEB J 2005;19(3):404-406. (Pubitemid 40316531)
36. Ayouba A, Tene G, Cunin P, et al.: Low rate of mother-tochild transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2003;34(3):274-280. (Pubitemid 37377360)
37. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al.: Envelopeconstrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004;303(5666):2019-2022. (Pubitemid 38393277)
38. Chohan B, Lang D, Sagar M, et al.: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005;79(10):6528-6531. (Pubitemid 40617257)
39. KeeleBFandDerdeynCA:Genetic andantigenic features of the transmitted virus. Curr Opinion HIV AIDS 2009;4(5):352-357.
40. Samleerat T, Braibant M, Jourdain G, et al.: Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01-AE. J Infect Dis 2008;198(6):868-876.
41. Rong R, Li B, Lynch RM, et al.: Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 2009;5(9):e1000594.
42. Moore PL, Ranchobe N, Lambson BE, et al.: Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009;5(9): e1000598.
43. Margolis L and Shattock R: Selective transmission of CCR5- utilizing HIV-1: The 'gatekeeper' problem resolved? Nat Rev Micro 2006;4(4):312-317.
44. Hong PWP, Nguyen S, Young S, et al.: Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J Virol 2007;81(15):8325-8336. (Pubitemid 47101517)
45. Hong PW, Flummerfelt KB, de PA, et al.: Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: Implications for structural analyses of gp120-DC-SIGN binding. J Virol 2002;76(24):12855- 12865. (Pubitemid 35386969)
46. Rong R, Gnanakaran S, Decker JM, et al.: Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 2007;81(11):5658-5668. (Pubitemid 46847005)
47. Gray ES, Moore PL, Pantophlet RA, and Morris L: N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol 2007;81(19):10769-10776. (Pubitemid 47463349)